Evaluating GS-4571 in Healthy and Obese Participants with Type 2 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to assess the safety and pharmacokinetics of the drug GS-4571 in three distinct groups: healthy participants, healthy non-diabetic obese participants, and non-obese participants with Type 2 Diabetes Mellitus (T2DM). The study will involve administering single and multiple ascending doses of GS-4571, with evaluations of how food intake and an acid-reducing agent (omeprazole) affect the drug's pharmacokinetics. Participants will be monitored for safety and tolerability throughout the study. The research is designed to gather critical data that could inform future treatment strategies for weight management and diabetes.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Age 18 through 55 years, for Parts A, B, and C, and 18 through 65 years, for Part D.
* Individuals must be glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve OR last dose was at least 6 months prior to screening.
* Part A (SAD) and Part B (Food/PPI Effect): eligible individuals in Cohorts 1-4, (optional cohort 5) and 6 will include healthy individuals with BMI of ≥ 19 and \< 30 kg/m\^2, and no significant medical history.

Individuals will also be in good general health as determined by the investigator at the screening evaluation performed no more than 28 days prior to the scheduled first dose.

* Part C (MAD in nondiabetic obese individuals): Eligible individuals in Cohorts 7-9 and (optional cohort 10) will be individuals with obesity with BMI ≥ 30 kg/m\^2 and \< 45 kg/m\^2 with a total body weight \> 50 kg, and nondiabetic (HbA1c \< 6.5%). Eligible individuals will also be individuals with stable body weight (\< 5% change) for 90 days prior to screening visit based on individual report.
* Part D (multiple doses in non-obese T2DM): eligible individuals in Cohort 11 will be individuals with T2DM HbA1c ≥ 7.0% and ≤ 10.5% with BMI of ≥ 19 and \< 30 kg/m\^2 and treated with diet and/or exercise, and/or metformin monotherapy.

Key Exclusion Criteria:

* Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol. This would include acute pancreatitis, or history of pancreatitis, acute gallbladder disease, and renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes \[with the exception of T2DM for individuals included in Part D only\]), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment.
* Current symptoms of diabetic retinopathy or examination indicating diabetic retinopathy within one year of screening.
* Any electrolyte disturbances identified at screening considered to be clinically significant in the opinion of the investigator (eg, hypokalemia, hypocalcemia, or hypomagnesemia).
* Any condition that could lead to electrolyte disturbances (eg, eating disorder) in the opinion of the investigator.
* History of syncope, palpitations, or unexplained dizziness.
* Active, or history of, significant cardiac disease or conduction abnormality
* History of implanted defibrillator or pacemaker.
* Have been treated with the following within 6 months prior to screening or is expected to receive these agents during the study: GLP-1RAs, systemic steroids, immunosuppressant therapies, or chemotherapeutic agents (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).
* Previously stopped use of GLP-1RAs secondary to severe side effects including nausea, constipation, diarrhea, or emesis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• Qps-Mra, Llc.
  Miami, Florida, United States Recruiting
• ICON Early Phase Services, LLC
  San Antonio, Texas, United States Recruiting
• Icon
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Study coordinator: Gilead Clinical Study Information Center
• Email: GileadClinicalTrials@gilead.com
• Phone: 1-833-445-3230 (GILEAD-0)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Family-based weight wellness with medically tailored groceries and group visits

  We’re testing a family-focused program that uses group medical visits and medically tailored groceries to help kids 12–17 with overweight or obesity, along with their parents.

  Recruiting at 2 sites Tufts University · Boston, Massachusetts and 1 other locations · NCT07717658

• Elecoglipron for weight management in adults with obesity or overweight with or without type 2 diabetes

  This study tests whether taking elecoglipron once daily helps adults with obesity or overweight, with or without type 2 diabetes, lose more weight than placebo when combined with diet and exercise.

  Recruiting at 220 sites Phase 3 AstraZeneca · Birmingham, Alabama and 324 other locations · NCT07667803

• Weight management program for breast cancer survivors in rural communities

  This program will test whether a 12-week remote WeCan-Rural program helps rural breast cancer survivors with obesity lose weight, ease symptoms, and lower heart disease risk.

  Recruiting at 5 sites Duke University · Durham, North Carolina and 4 other locations · NCT07426952

• Hope‑D digital weight management program for pregnancy and the first six months after birth

  This test tries the Hope‑D digital weight management program with pregnant women who had a pre-pregnancy BMI of 30 or higher to support weight during pregnancy and through six months postpartum.

  Recruiting Turku University Hospital · Turku, Finland · NCT07272824

• Oral ecnoglutide tablets for weight management in Chinese adults with overweight or obesity

  This trial will test whether daily or weekly oral ecnoglutide tablets help Chinese adults with overweight or obesity and are safe and well tolerated.

  Recruiting Phase 1/2 Hangzhou Sciwind Biosciences Co., Ltd. · Beijing, Beijing Municipality · NCT07243171

• Improving team-based biopsychosocial training so clinics can deliver recommended obesity care

  This project will test two training methods to help clinic teams (primary care clinicians, behavioral health staff, dietitians, and community health workers) deliver USPSTF-recommended obesity care to patients at Federally Qualified Health Centers.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07049861

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.